Urovant Sciences Ltd (UROV1)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Keith A. Katkin
Employees:
0
5151 CALIFORNIA AVENUE, SUITE 250, IRVINE, CA 92617
949-226-6029

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. The company is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom.

Data derived from most recent annual or quarterly report
Market Cap 531.753 Million Shares Outstanding32.743 Million Avg 30-day Volume 143.554 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-3.47
Price to Revenue0.0 Debt to Equity0.0 EBITDA-126.705 Million
Price to Book Value0.0 Operating Margin0.0 Enterprise Value446.258 Million
Current Ratio2.128 EPS Growth0 Quick Ratio1.763
1 Yr BETA 0.6506 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth-26.7132 Altman Z-Score-7.7194 Free Cash Flow to Firm 0
View SEC Filings from UROV1 instead.

View recent insider trading info

Urovant Sciences Ltd YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding UROV1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding UROV1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

POTTER MYRTLE S

  • Director
 No longer subject to file 2021-03-29 0

BANSAL AJAY SEE REMARKS

  • Officer
 No longer subject to file 2021-03-29 0

OCAMPO CHRISTINE PAO; CAO/UROVANT SCIENCES,INC.

  • Officer
 No longer subject to file 2021-03-29 0

LEGAULT PIERRE

  • Director
 No longer subject to file 2021-03-29 0

HINDMAN JAMES M.

  • Director
 No longer subject to file 2021-03-29 0

ROBINSON JAMES A. JR. PEO;CEO/UROVANT SCIENCES, INC.

  • Officer
  • Director
 No longer subject to file 2021-03-29 0

SMITH BRYAN E. GC/UROVANT SCIENCES, INC.

  • Officer
 No longer subject to file 2021-03-29 0

KURSTJENS SEF

  • Director
 No longer subject to file 2021-03-29 0

HAAG-MOLKENTELLER CORNELIA CMO/UROVANT SCIENCES, INC.

  • Officer
 No longer subject to file 2021-03-29 0

JOHNSTON WALT SEE REMARKS

  • Officer
 No longer subject to file 2021-03-29 0

KATKIN KEITH PEO;CEO/UROVANT SCIENCES, INC.

  • Officer
  • Director
 199,680 2020-02-19 0

SUMITOMO CHEMICAL CO., LTD.

DAINIPPON SUMITOMO PHARMA CO LTD

SUMITOVANT BIOPHARMA LTD.

  • 10% Owner
  • SEE FOOTNOTE (1)SEE FOOTNOTE (1)
22,963,263 2020-02-19 0

ROIVANT SCIENCES LTD.

  • 10% Owner
 No longer subject to file 2019-12-27 0

NISHINAKA SHIGEYUKI

  • Director
 0 2019-12-27 0

VIKING GLOBAL PERFORMANCE LLC

VIKING GLOBAL EQUITIES LP

VIKING GLOBAL EQUITIES II LP

VGE III PORTFOLIO LTD.

VIKING GLOBAL EQUITIES MASTER LTD.

VIKING LONG FUND GP LLC

VIKING LONG FUND MASTER LTD.

HALVORSEN OLE ANDREAS

OTT DAVID C.

SHABET ROSE SHARON

  • 10% Owner
  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
 No longer subject to file 2019-07-10 0

VIKING GLOBAL INVESTORS LP

VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

VIKING GLOBAL OPPORTUNITIES GP LLC

HALVORSEN OLE ANDREAS

OTT DAVID C.

SHABET ROSE SHARON

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
 No longer subject to file 2019-07-10 0

QVT ASSOCIATES GP LLC

QVT FINANCIAL INVESTMENT CAYMAN LTD.

  • 10% Owner
 No longer subject to file 2019-07-10 0

MACHADO PATRICK

  • FORMER 10% OWNER
 No longer subject to file 2019-07-10 0

DEXXON HOLDINGS LTD.

DEXCEL PHARMA TECHNOLOGIES LTD.

OREN DAN

  • SEE REMARKSSEE REMARKSSEE REMARKS
 No longer subject to file 2019-07-10 0

LO ANDREW

  • FORMER 10% OWNER
 No longer subject to file 2019-07-10 0

SVF INVESTMENTS (UK) LTD

SOFTBANK VISION FUND L.P.

SVF GP (JERSEY) LTD

SVF HOLDINGS (UK) LLP

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
 No longer subject to file 2019-07-10 0

TORTI FRANK

  • Director
 0 2019-07-09 0

EBERSOLE NORI SVP;CHRO/UROVANT SCIENCES, INC

  • Officer
 0 2019-01-06 0

MCFADDEN MICHAEL E. CCO/UROVANT SCIENCES, INC.

  • Officer
 0 2019-01-06 0

VIKING GLOBAL EQUITIES MASTER LTD.

  • 10% Owner
 22,703,669 2019-01-01 0

POTTER MYRTLE S

POTTER MYRTLE S

  • Director
 0 2018-11-21 0

VIKING GLOBAL PERFORMANCE LLC

VIKING GLOBAL EQUITIES LP

VIKING GLOBAL EQUITIES II LP

VGE III PORTFOLIO LTD.

VIKING LONG FUND GP LLC

VIKING LONG FUND MASTER LTD.

  • 10% Owner
 22,703,669 2018-10-01 0

QVT ASSOCIATES GP LLC

QVT FUND V LP

  • 10% Owner
 22,703,669 2018-10-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
UROVANT SCIENCES LTD UROV 2021-03-29 19:15:03 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-29 18:45:02 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-29 18:15:02 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-29 17:45:03 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-29 17:15:03 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-29 16:45:03 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-29 16:15:02 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-29 15:45:03 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-29 15:15:03 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-29 14:45:03 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-29 14:15:03 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-29 13:45:03 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-29 13:15:03 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-29 12:45:03 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-26 22:15:03 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-26 21:45:03 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-26 21:15:03 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-26 20:45:02 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-26 20:15:04 UTC -3.1537 3.2237 400000
UROVANT SCIENCES LTD UROV 2021-03-26 19:45:03 UTC -3.1537 3.2237 400000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments